NCT07405164 2026-04-17
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3 Recruiting
Clinical Trials
4 trialsNCT05327686 2026-04-08
SAMURAI
NRG Oncology
Phase 2 Recruiting
NCT05024214 2026-03-25
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
3D Medicines
Phase 1/2 Recruiting
NCT05733715 2026-03-24
Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Recruiting